Since its establishment, the company has been awarded the honorary titles of star enterprise, excellent enterprise and harmonious labor relations enterprise in Hebei Province, and Xingquan brand is a famous trademark in Hebei Province. In 2005, the company was awarded "AAA Credit Customer of 2005" by Hebei Branch of Agricultural Bank of China.
The company's leading product, Compound Aloe Capsule, is a pure compound preparation of traditional Chinese medicine successfully developed by the company on 1985. It is a national second-class protected variety of traditional Chinese medicine and is exclusively produced in China. It takes natural aloe imported from Africa as the main raw material, and has the effects of clearing liver, relaxing bowels, calming the heart and calming the nerves. For heart and liver fire, constipation, abdominal distension and abdominal pain, irritability and insomnia. The product has the characteristics of definite curative effect, mild action, quick onset, good stability, less adverse reactions, less dosage, convenient administration and low price. It has been widely welcomed by patients and doctors for more than 20 years, and has a high market coverage and high reputation among domestic laxatives. In 2009, relying on the powerful Wanbang pharmaceutical platform, the company's sales performance reached a new high.
Companies adhere to the people-oriented, strengthen team building, and vigorously introduce professional and technical personnel. According to the enterprise orientation of "Chinese medicine laxative product leader" and "Chinese medicine hypoglycemic product innovator", the company implemented the strategy of product innovation and patent development, carried out in-depth development of compound aloe capsules, innovated and developed a series of Chinese medicine hypoglycemic products, established the company's competitive advantages in constipation and Chinese medicine hypoglycemic products, and strived to become a well-known enterprise in the field of Chinese medicine laxative hypoglycemic products. Shanghai Kaimao Biomedical Co., Ltd. was established in June 2008 165438+ 10/9 with a registered capital of10000000 yuan in Wu Bai. It was jointly funded by Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. and CHEMO Group of Spain. Chemo Group, Spain Jinwu Pharmaceutical Co., Ltd. is a company integrating R&D, chemicals, medicine and biomedicine production and sales, and has its own R&D base, production enterprises and commercial network all over the world. Committed to the research, development, production and commercialization of pharmaceutical products worldwide, its purpose is to provide high-quality products through continuous technological innovation and its application in product research and development, and make unremitting efforts to achieve human health.
The company is located in caohejing High-tech Industrial Park, Xuhui District, covering an area of 30 mu. It has three genetic engineering product workshops and two freeze-dried powder injection workshops, with advanced production technology and equipment. The company mainly features biotechnology drugs and anti-tumor drugs, and the establishment of the joint venture company is an important step for the pharmaceutical business to enter the international journey.
Kaimao Bio has more than 65,438+00 years of experience in R&D, production and operation: it has the core resources of the Enterprise Technology Center of Shanghai Fosun Pharma (Group) Co., Ltd.; It has the marketing network and production quality research and development resources of Jiangsu Wanbang Medicine all over the country; It has the global sales network and biotechnology research and development resources of CHEMO Group in Spain.
The company's main products are: Clone γ (recombinant interferon γ for injection), Clone Yibao (recombinant human erythropoietin for injection), national first-class new drug Sikaitong (recombinant streptokinase for injection), and Luo Yi Ze (pemetrexed disodium for injection), an important achievement in the research and development of new anti-tumor fields in recent years. The company will continue to develop new drugs in the field of tumor treatment, and strive to develop a number of new drugs with independent intellectual property rights and market competitiveness from the perspective of drug innovation, effectiveness and safety. At the same time, we actively organize and enhance the competitiveness of existing products in the international market, and have obtained registration certificates from many countries such as South America, Eastern Europe and Southeast Asia.
Shanghai Zhao Hui Drug Co., Ltd.
Shanghai Zhao Hui Pharmaceutical Co., Ltd, formerly known as Zhao Hui Pharmaceutical Factory of the Second Military Medical University, was established in 1958. At the end of 1998, according to the unified deployment of the Central Military Commission, it was handed over to the local government of Baoshan District for management. At the beginning of 1999, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (formerly Shanghai Fosun Industrial Co., Ltd.) participated in the enterprise operation and established Shanghai Fosun Zhao Hui Pharmaceutical Co., Ltd. with a registered capital of100000 yuan. In February 2005, the registered capital of the enterprise increased to 1 100 million yuan. In July 2007, due to the need to create its own brand and establish its own brand image, the enterprise was renamed as Shanghai Zhao Hui Pharmaceutical Co., Ltd., and from June 5, 2008 to February 2008, it was placed under the management of Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
The new factory of Shanghai Zhao Hui Pharmaceutical Co., Ltd. with an investment of 654.38+0.4 billion yuan is located in Luodian Industrial Park, Baoshan District, Shanghai, and was officially put into operation at the end of 2002. The company covers an area of 100 mu, with a building area of 1 1026 square meters, a total building area of 20,465 square meters, a green area of 28,445 square meters and a green rate of 44.5%.
From June 5, 2003 to 2003 10, eight production lines of Shanghai Zhao Hui Pharmaceutical Co., Ltd., including tablets, capsules (all containing antineoplastic drugs), granules, ointments (hormones), small-volume injections and raw materials (lidocaine hydrochloride), successfully passed the GMP on-site verification of the State Pharmaceutical Products Supervision Administration and obtained GMP certificates. In May 2003, the company's ointment (non-hormone) also passed GMP certification. In February 2007, the company passed the GMP review of the US Food and Drug Administration and the US Food and Drug Administration in Shanghai.
In May, 2009, the APIs Bemag and Acetylglutamine obtained GMP certificates. Calcium dobesilate, the raw material drug, obtained GMP certificate in July 2009; Perphenazine obtained GMP certificate in March, 20 1 1.
The company's main products involve endocrine, anti-tumor, dermatosis, analgesia and other fields. You Ke Penciclovir Cream, Yike Exemestane Tablets, Foucault Doxorubicin Capsules, Yike Meloxicam Tablets, Calcium Dobesilate Capsules, Pioglitazone Hydrochloride Tablets and other varieties in the new drug series have all been selected into the Shanghai High-tech Transformation Project, and have entered the National Medical Insurance Category A and B catalogue.